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Received June 16, 2015; accepted January 6, 2016AbstractBackground: Predicting acute renal failure in patients with severe sepsis is important, because patients may need renal replacement therapy
(RRT). Neutrophil gelatinase-associated lipocalin (NGAL) has been evaluated for its ability to detect and predict acute kidney injury (AKI) in
critically ill patients. This study aimed to assess the predictive value of plasma NGAL for acute renal failure in adult severely septic patients.
Methods: Thirty healthy adults and 85 adult patients admitted to the medical intensive care unit (ICU) were enrolled. Serum creatinine, plasma
NGAL, and interleukin (IL)-6, IL-10, and IL-17 levels were evaluated. AKI was classified as Risk, Injury, Failure, Loss of kidney function, and
End-stage kidney disease (RIFLE).
Results: RIFLE-Failure (RIFLE-F) developed in 30 of 76 (39.5%) patients with severe sepsis without chronic kidney disease within 7 days after
ICU admission. Serum creatinine, plasma NGAL, IL-6, and IL-10 could predict RIFLE-F within 7 days after ICU admission. The discriminatory
power of plasma NGAL was not significant for predicting hospital mortality. The area under the receiver operating characteristic curve of plasma
NGAL was not higher than that of serum creatinine in predicting RIFLE-F within 7 days.
Conclusion: Plasma NGAL is a useful tool for predicting acute renal failure in adult patients with severe sepsis. Serum creatinine has a similar
ability to detect RIFLE-F occurrence.
Copyright © 2016, the Chinese Medical Association. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Sepsis is a leading cause of acute kidney injury (AKI) in
critically ill patients.1,2 AKI is an important issue that in-
creases mortality among patients with severe sepsis.3 In cur-
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license (http://creativecommons.org/licenses/by-nc-nd/4.0/).creatinine is the most common indicator of renal dysfunction.
However, its slow rate of change has limited its application for
diagnosing and predicting AKI.4e6 Recently, several studies
have investigated the early detection and prediction of AKI by
neutrophil gelatinase-associated lipocalin (NGAL) as a novel
biomarker,4,6e11 although NGAL from activated neutrophils is
also a marker of infection and systemic inflammation.12e14
When severe sepsis is complicated by AKI, the predictive
performance of NGAL may be affected.
Sepsis is a complicated syndrome in which proin-
flammatory cytokines like interleukin (IL)-6 and anti-
inflammatory cytokines like IL-10 are expressed simulta-
neously.15 Previous studies have shown that elevated levels ofsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND
Fig. 1. The study profile shows 115 individuals including 30 healthy adults and
85 patients with severe sepsis admitted to the ICU. Nine patients had ESRD
and received regular hemodialysis. Seventy-six adult patients did not have a
history of CKD or ESRD. In the 76 patients with severe sepsis, 30 patients had
RIFLE-F within 7 days after ICU admission and 46 patients did not.
CKD ¼ chronic kidney disease; ESRD ¼ end-stage renal disease;
ICU ¼ intensive care unit; RIFLE-F ¼ Failure stage of Risk, Injury, Failure,
Loss of kidney function, and End-stage kidney disease classification.
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patients with sepsis and AKI.16e18 IL-17 is reported to play a
role in the pathogenesis of AKI.19 Can IL-6, IL-10, and IL-17
also be useful markers for acute renal failure in patients with
severe sepsis?
The optimal timing for initiating renal replacement therapy
(RRT) for AKI in patients with severe sepsis has not been
established. The Acute Dialysis Quality Initiative (ADQI)
proposed a consensus definition for the Risk, Injury, Failure,
Loss of kidney function, and End-stage kidney disease
(RIFLE) classification for AKI, grading severity by risk,
injury, and failure.20 Two studies suggested that early RRT
prior to RIFLE-Failure (F) stage may improve the outcome of
AKI patients who need RRT.21,22 Promising AKI biomarkers
to predict RIFLE-F may allow for the optimal timing of
initiating RRT.
The main purpose of this study was to evaluate the potential
for plasma NGAL and cytokines to predict RIFLE-F and RRT
initiation in patients with severe sepsis.
2. Methods2.1. ParticipantsThis was a prospective observational study of 115 patients
who had undergone tests for plasma neutrophil gelatinase-
associated lipocalin (NGAL) and cytokines. Seventy-six
adult patients did not have a history of chronic kidney dis-
ease (CKD) or end-stage renal disease. CKD was defined as
decreased kidney function (estimated glomerular filtration
rate < 60 mL/min/1.73 m2) for  3 months.23 Nine patients
had end-stage renal disease (RIFLE-E) and received regular
hemodialysis. These 85 patients were admitted to the medical
intensive care unit (ICU) at Chang Gung Memorial Hospital in
Keelung, Taiwan due to severe sepsis from July 2008 to
August 2010. Thirty healthy adults were recruited from the
hospital's health evaluation center (Fig. 1). The ICU was a
closed-format unit staffed by medical intensivists. The hos-
pital's Institutional Review Board approved the study (99-
2232B), and the patients' families provided informed consent.2.2. Clinical data collection and definitionsWithin the first 24 hours of admission, data on patients' age,
gender, medical history, infection source, and comorbidity
were recorded. Standard treatment, including fluid resuscita-
tion, broad-spectrum antibiotics, drainage, and basic support
were provided to all patients.24 Antibiotics and fluid resusci-
tation were started as soon as possible after sepsis was
diagnosed.
Severe sepsis and septic shock were defined according to
the criteria of the Consensus Conference.25 Systemic inflam-
matory response syndrome (SIRS) was defined as two or more
of the following criteria: (1) body temperature > 38C
or < 36C; (2) respiratory rate > 24 breaths/min; (3) heart
rate > 90 beats/min; and (4) white blood count > 12,000/mL
or < 4000/mL or > 10% bands. Sepsis was defined as SIRSbased on confirmed or suspected microbial etiology, while
severe sepsis was defined as sepsis with one or more of organ
dysfunction or with hypotension. Septic shock was defined as
sepsis with hypotension unresponsive to fluid resuscitation and
further requiring vasopressors to maintain blood pressure on
admission day. Survivors were defined as patients who were
still alive 28 days after ICU admission. Disease severity was
assessed by the Acute Physiology and Chronic Health Eval-
uation (APACHE) II score using data within 24 hours of
admission.26
AKI was defined using serum creatinine and urine output
criteria to determine the RIFLE classification of all patients.
The criteria that led to the worst possible classification were
used. Because some patients (n ¼ 8, 10.5%) did not have
baseline renal function, a hypothetical baseline serum creati-
nine was estimated for a given patient assuming a normal
glomerular filtration rate (75 mL/min per 1.73 m2) with
modification of diet in renal disease (MDRD) formula, as
recommended by the ADQI working group.20,232.3. NGAL and cytokine measurementsPlasma samples were obtained from veins within 24 hours
after admission to the medical ICU. All plasma samples were
stored at 80C until centrifugation within 2 hours. Plasma
levels of IL-6, IL-17, and NGAL were measured by human IL-
6, IL-17, and NGAL enzyme-linked immunosorbent assay
(ELISA) kits (R & D Systems, Minneapolis, MN, USA).
Plasma level of IL-10 was measured by human IL-10 ELISA
kit (Pierce Biotechnology, Rockford, IL, USA).2.4. Statistical analysisStatistical analysis was performed using SPSS for Windows
version 17.0 (SPSS Inc., Chicago, IL, USA). Differences in
Table 1
Clinical characteristics of patients with severe sepsis.
Non-RIFLE-F
(n ¼ 46)
RIFLE-F
(n ¼ 30)
p
Age (y) 73.9 ± 2.0 71.3 ± 2.3 0.400
Male sex 32 (69.6) 17 (56.7) 0.251
APACHE II score 23.4 ± 0.9 28.4 ± 1.3 0.001
Plasma NGAL (ng/mL) 217.2 ± 16.8 350.2 ± 32.2 0.001
Serum Cr (mg/dL) 1.1 ± 0.1 3.0 ± 0.3 < 0.001
Plasma IL-6 (pg/mL) 121.2 ± 20.7 225.0 ± 34.8 0.013
Plasma IL-10 (pg/mL) 28.3 ± 8.1 174.4 ± 52.4 < 0.001
Plasma IL-17 (pg/mL) 10.2 ± 3.2 13.0 ± 6.5 0.576
History
COPD 11 (23.9) 6 (20.0) 0.689
Heart failure 4 (8.7) 0 (0.0) 0.097
Hypertension 16 (34.8) 13 (43.3) 0.453
Liver cirrhosis 0 (0.0) 6 (20.0) 0.002
Diabetes mellitus 16 (34.8) 9 (30.0) 0.664
Old CVA 18 (39.1) 6 (20.0) 0.079
Source of infection 0.431
Pneumonia 41 (89.1) 25 (83.3)
Urinary tract infection 4 (8.7) 3 (10.0)
Others 1 (2.2) 2 (8.7)
Advent events
Septic shock 23 (50.0) 24 (80.0) 0.008
Bacteremia 6 (13.0) 13 (43.3) 0.003
Jaundice 0 (0.0) 6 (20.0) 0.002
Thrombocytopenia 9 (19.6) 13 (43.3) 0.026
Gastrointestinal bleeding 8 (17.4) 6 (20.0) 0.774
Mortality within 28 d 6 (13.0) 16 (53.3) < 0.001
Data are presented as mean ± standard error or n (%). Statistical comparison
was performed with ManneWhitney U test or c2 test.
APACHE ¼ Acute Physiology and Chronic Health Evaluation;
COPD ¼ chronic obstructive pulmonary disease; Cr ¼ creatinine;
CVA ¼ cerebrovascular accident; IL ¼ interleukin; NGAL ¼ neutrophil
gelatinase-associated lipocalin; RIFLE-F ¼ Failure stage of Risk, Injury,
Failure, Loss of kidney function, and End-stage kidney disease classification.
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plasma NGAL between the two groups were analyzed by
ManneWhitney U test. Differences in categorical variables
such as gender, medical history, comorbidity, and mortality
between the two groups were compared using c2 test or
Fisher's exact test. Area under the receiver operating charac-
teristic curve (AUROC) was calculated to analyze the
discriminatory power of predictive accuracy for RIFLE-F,
RRT, and mortality. An appropriate cutoff value of plasma
NGAL (150 ng/mL) was chosen according to meta-analysis of
the available NGAL studies.27 Reasonable cutoff values of
cytokines were chosen according to the ROC analysis of
healthy adults and patients with RIFLE-E. Sensitivity and
specificity were defined as the proportion of patients correctly
identified by the test as abnormal and the proportion of neg-
atives correctly identified, respectively. Positive predictive
value (PPV) was the proportion of patients with RIFLE-F
within 7 days among those with positive test results. The
negative predictive value (NPV) was the proportion of patients
without RIFLE-F within 7 days among those with negative test
results. For positive test results, the likelihood ratio was the
odds of positive test results in patients with RIFLE-F within
7 days, versus positive test results in patients without RIFLE-F
within 7 days. For negative test results, the likelihood ratio
was the odds of negative test results in patients without
RIFLE-F within 7 days, versus negative test results in patients
with RIFLE-F within 7 days. A value of p < 0.05 was
considered statistically significant.
3. Results
The clinical characteristics and biomarkers of 76 patients
with severe sepsis without chronic kidney disease are shown in
Table 1. The power of the sample size for plasma NGAL and
serum creatinine, IL-6, IL-10, and IL-17 was 98%, 100%,
77%, 91%, and 7%, respectively.3.1. Comparison of non-RIFLE-F and RIFLE-FIn the 76 patients with severe sepsis, 30 (39.5%) had
RIFLE-F within 7 days after ICU admission. Serum creatinine
and plasma NGAL, IL-6, and IL-10 levels in RIFLE-F patients
were significantly higher than in non-RIFLE-F patients. The
APACHE II score and mortality within 28 days showed sig-
nificant differences between RIFLE-F and non-RIFLE-F pa-
tients. There were no significant differences in age, sex, and
history (except liver cirrhosis) between RIFLE-F and non-
RIFLE-F patients. The proportions of septic shock, bacter-
emia, jaundice, and thrombocytopenia were significantly
higher in RIFLE-F patients compared to non-RIFLE-F
patients.3.2. Comparison of biomarkers for predicting RIFLE-F
and deathSerum creatinine (area under ROC curve ¼ 0.894,
p < 0.001) and plasma IL-10 (AUROC ¼ 0.818, p < 0.001)had good discriminatory power for predicting RIFLE-F within
7 days (Fig. 2 and Table 2). Plasma NGAL (AUROC ¼ 0.731,
p ¼ 0.001) showed fair discrimination for predicting RIFLE-F
after ICU admission.
The demographic data of healthy controls and patients with
severe sepsis with RIFLE-E are shown in Table 3. A reason-
able cutoff value was chosen according to the ROC analysis of
the two groups. These cutoff values were used to predict the
development of RIFLE-F. Table 4 lists the calculated sensi-
tivity, specificity, PPV, NPV, likelihood ratio of positive test,
and likelihood ratio of negative test with the cutoff concen-
trations of plasma NGAL, serum creatinine, IL-6, and IL-10
levels for the prediction of RIFLE-F within 7 days.
We also analyzed mortality within 28 days by the bio-
markers (Table 5). Plasma IL-6 yielded an AUROC of 0.699
(Fig. 3 and Table 6). Both serum creatinine and IL-10 could
significantly predict hospital mortality, but their discrimina-
tory power was poor. Plasma NGAL had no value in predicting
patient mortality.
4. Discussion
Plasma NGAL has been investigated in various settings of
AKI, such as after cardiac surgery,4,6 in patients receiving
Fig. 2. The ROC curves of plasma NGAL and serum Cr, IL-6, IL-10 and IL-17 for RIFLE-F within 7 days after admission. Serum Cr (area under ROC ¼ 0.894,
p < 0.001) and plasma IL-10 (area under ROC ¼ 0.818, p < 0.001) had good discriminatory power for predicting RIFLE-F within 7 days. Cr ¼ creatinine;
IL ¼ interleukin; NGAL ¼ neutrophil gelatinase-associated lipocalin; RIFLE-F ¼ Failure stage of Risk, Injury, Failure, Loss of kidney function, and End-stage
kidney disease classification; ROC ¼ receiver operating characteristic.
Table 2
AUROC analysis of biomarkers for RIFLE-F within 7 days in patients with
severe sepsis.
AUROC 95% CI p
Plasma NGAL 0.731 ± 0.061 0.612 e 0.850 0.001
Serum Cr 0.894 ± 0.043 0.809 e 0.979 < 0.001
Plasma IL-6 0.669 ± 0.065 0.542 e 0.796 0.013
Plasma IL-10 0.818 ± 0.050 0.719 e 0.916 < 0.001
Plasma IL-17 0.537 ± 0.067 0.405 e 0.669 0.588
Data are presented as mean ± standard error.
AUROC ¼ area under the receiver operating characteristic curve;
Cr ¼ creatinine; CI ¼ confidence interval; IL ¼ interleukin;
NGAL ¼ neutrophil gelatinase-associated lipocalin; RIFLE-F ¼ Failure stage
of Risk, Injury, Failure, Loss of kidney function, and End-stage kidney disease
classification.
Table 3
Demographic data of healthy controls and severely septic patients with
RIFLE-E.
Controls (n ¼ 30) RIFLE-E (n ¼ 9)
Age (y) 60.7 ± 1.9 67.7 ± 3.6
Male sex* 22 (73.3) 2 (22.2)
Plasma NGAL (ng/mL)* 74.8 ± 6.0 494.8 ± 44.8
Serum Cr (mg/dL)* 0.9 ± 0.0 5.2 ± 1.2
Plasma IL-6 (pg/mL)* 3.7 ± 2.1 209.9 ± 60.8
Plasma IL-10 (pg/mL)* 6.7 ± 1.8 89.9 ± 35.7
Plasma IL-17 (pg/mL) 1.1 ± 0.6 4.4 ± 3.8
Data are presented as mean ± standard error or n (%).
*p < 0.05.
Cr ¼ creatinine; IL ¼ interleukin; NGAL ¼ neutrophil gelatinase-associated
lipocalin; RIFLE-E ¼ End-stage kidney disease of Risk, Injury, Failure,
Loss of kidney function, and End-stage kidney disease classification.
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patients.9,11 It appears to be a promising biomarker, especially
in the pediatric population.6,8,11 In contrast to pediatric pa-
tients, the adult population has a proportion of comorbidities
and underlying CKD. The timing and severity of renal insult
are known in those patients with surgery and intravenous
contrast exposure but are difficult to determine during sepsis.
This observational study evaluated the predictive value of
plasma NGAL for acute renal failure in adult patients with
severe sepsis and found that plasma NGAL levels weresignificantly higher in patients with RIFLE-F compared to
non-RIFLE-F patients. Plasma NGAL had fair discriminatory
power to predict RIFLE-F but did not have good prognostic
value for clinical outcomes. Plasma NGAL was not superior to
serum creatinine in the prediction of RIFLE-F within 7 days in
patients with severe sepsis.
In the current study, prediction of the development of
RIFLE-F by plasma NGAL was similar to that by serum
creatinine, which is consistent with results of the study by de
Geus et al28 performed in 632 patients upon ICU admission. In
Table 4
Cutoff values and reliability of biomarkers for the prediction of RIFLE-F
within 7 days in patients with severe sepsis.
Cutoff values Plasma NGAL
150.0 ng/mL
Serum Cr
1.5 mg/dL
Plasma IL-6
83.9 pg/mL
Plasma IL-10
13.2 pg/mL
Sensitivity (%) 90.0 83.3 60.0 93.3
Specificity (%) 34.8 87.0 43.5 54.3
PPV (%) 47.4 80.6 40.9 57.1
NPV (%) 84.2 88.9 62.5 92.6
LR of positive test 1.38 6.39 1.06 2.04
LR of negative test 3.48 5.22 1.09 8.15
Cr ¼ creatinine; IL ¼ interleukin; LR ¼ likelihood ratio; NGAL ¼ neutrophil
gelatinase-associated lipocalin; NPV ¼ negative predictive value;
PPV ¼ positive predictive value; RIFLE-F ¼ Failure stage of Risk, Injury,
Failure, Loss of kidney function, and End-stage kidney disease classification.
Table 5
Analysis of mortality within 28 days by biomarkers.
Survivors
(n ¼ 54)
Non-survivors
(n ¼ 22)
p
Plasma NGAL (ng/mL) 258.1 ± 19.8 298.1 ± 37.8 0.499
Serum Cr (mg/dL) 1.7 ± 0.2 2.2 ± 0.3 0.044
Plasma IL-6 (pg/mL) 127.9 ± 20.6 246.2 ± 39.2 0.007
Plasma IL-10 (pg/mL) 65.8 ± 21.4 135.7 ± 57.5 0.030
Plasma IL-17 (pg/mL) 8.1 ± 2.6 19.3 ± 8.9 0.326
Data are presented as mean ± standard error. Statistical comparison was
performed with ManneWhitney U test.
Cr ¼ creatinine; IL ¼ interleukin; NGAL ¼ neutrophil gelatinase-associated
lipocalin.
Fig. 3. The ROC curves of plasma NGAL and serum Cr, IL-6, IL-10, and IL-17 for
0.699. Both serum Cr and IL-10 could statistically predict hospital mortality, but th
patient mortality. Cr ¼ creatinine; IL ¼ interleukin; NGAL ¼ neutrophil gelatina
Table 6
AUROC analysis of the biomarkers for mortality within 28 days.
AUROC 95% CI p
Plasma NGAL 0.550 ± 0.075 0.404e0.696 0.499
Serum Cr 0.648 ± 0.068 0.514e0.781 0.044
Plasma IL-6 0.699 ± 0.070 0.561e0.837 0.007
Plasma IL-10 0.660 ± 0.066 0.529e0.790 0.030
Plasma IL-17 0.570 ± 0.079 0.414e0.725 0.342
Data are presented as mean ± standard error.
AUROC ¼ area under the receiver operating characteristic curve;
CI ¼ confidence interval; Cr ¼ creatinine; IL ¼ interleukin;
NGAL ¼ neutrophil gelatinase-associated lipocalin.
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filtration rate had similar predictive accuracy for AKI in ICU
patients compared to plasma NGAL, even though patients with
sepsis only accounted for 6.8% (43/632). Martensson et al29
also reported that plasma NGAL was a poor predictor
(AUROC ¼ 0.67) for AKI in patients with septic shock.
Possible explanations include the unknown timing of renal
insult and the influence of the inflammatory state on plasma
NGAL production.
Sepsis is a major precipitating factor for AKI in critically ill
patients.1,2 Plasma NGAL increases within 2 hours after acute
tubular damage,6,30 but serum creatinine has a slow rate of
change of 24e72 hours following renal injury.4,6 Nevertheless,
the timing of renal insult in patients with severe sepsis cannotmortality within 28 days. Plasma IL-6 yielded an area under the ROC curve of
eir discriminatory power was poor. Plasma NGAL had no value in predicting
se-associated lipocalin; ROC ¼ receiver operating characteristic.
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predictive value over serum creatinine in ICU patients.
NGAL is secreted from activated neutrophils and expressed
in organs containing epithelial tissues, including the lungs,
liver, kidney, and gastrointestinal tract.13,31,32 There are high
concentrations of NGAL in plasma when acute tubular dam-
age develops.6,30 Moreover, NGAL is also expressed in high
concentrations during inflammation or infection, including
sepsis and malignancy.29,33 Therefore, plasma NGAL may
have higher expression not only in renal tubular damage but
also in severe sepsis. This may influence its diagnostic and
predictive value for acute renal failure in patients with severe
sepsis.
This study used IL-6 and IL-10 as reference markers of
sepsis with acute renal failure. Early inflammatory response in
sepsis is characterized by the release of several proin-
flammatory cytokines, including IL-6,15,34 although its role in
AKI is not well characterized. To date, elevated IL-6 levels
might predict sustained AKI after ischemic injury in renal
allografts.35 Simmons et al17 reported that increased IL-6
levels would predict mortality in patients with sepsis and
AKI. In the present study, IL-6 level was significantly higher
in RIFLE-F patients than in non-RIFLE-F patients. Similarly,
elevated concentrations of IL-6 could predict AKI in placebo-
treated patients with severe sepsis in the PROWESS (Re-
combinant Human Activated Protein C Worldwide Evaluation
in Severe Sepsis) study.16 In this study, plasma IL-10 level
showed significant difference between RIFLE-F and non-
RIFLE-F groups in patients with severe sepsis. This was
similar to the study of Ahlstr€om et al,18 in which patients with
acute renal failure showed significantly higher plasma levels
of IL-10 than patients without acute renal failure. Although
IL-17 is involved in the pathogenesis of AKI, plasma IL-17
levels were not associated with RIFLE-F development
within 7 days and 28-day mortality.
There was one limitation to this study. The RIFLE classi-
fication is recommended to define and stage AKI in clinical
studies. Baseline serum creatinine should be known, but some
patients did not have available baseline serum creatinine for
calculation of the proportional decrease of renal function.
Thus, an estimated baseline serum creatinine, based on the
MDRD equation proposed by the ADQI in previous studies,
was used.36,37 This may have overestimated the baseline,
especially when patients have low body mass and low creat-
inine, and may have influenced the results.
In conclusion, serum creatinine is not inferior to plasma
NGAL in predicting RIFLE-F within 7 days in adult patients
with severe sepsis. Nevertheless, both serum creatinine and
plasma NGAL do not have good discrimination for hospital
mortality. Based on these results, serum creatinine might be
used first to evaluate acute renal failure and to decide on RRT
initiation.
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